Literature DB >> 33889951

Biallelic loss-of-function variations in PRDX3 cause cerebellar ataxia.

Adriana P Rebelo1, Ilse Eidhof2, Vivian P Cintra1, Léna Guillot-Noel3,4, Claudia V Pereira5, Dagmar Timmann6, Andreas Traschütz7,8, Ludger Schöls7,8, Giulia Coarelli3, Alexandra Durr3,9, Mathieu Anheim10,11, Christine Tranchant10,11, Bart van de Warrenburg12, Claire Guissart13, Michel Koenig13, Jack Howell1, Carlos T Moraes5, Annette Schenck2, Giovanni Stevanin3,4, Stephan Züchner1, Matthis Synofzik7,8.   

Abstract

Peroxiredoxin 3 (PRDX3) belongs to a superfamily of peroxidases that function as protective antioxidant enzymes. Among the six isoforms (PRDX1-PRDX6), PRDX3 is the only protein exclusively localized to the mitochondria, which are the main source of reactive oxygen species. Excessive levels of reactive oxygen species are harmful to cells, inducing mitochondrial dysfunction, DNA damage, lipid and protein oxidation and ultimately apoptosis. Neuronal cell damage induced by oxidative stress has been associated with numerous neurodegenerative disorders including Alzheimer's and Parkinson's diseases.  Leveraging the large aggregation of genomic ataxia datasets from the PREPARE (Preparing for Therapies in Autosomal Recessive Ataxias) network, we identified recessive mutations in PRDX3 as the genetic cause of cerebellar ataxia in five unrelated families, providing further evidence for oxidative stress in the pathogenesis of neurodegeneration. The clinical presentation of individuals with PRDX3 mutations consists of mild-to-moderate progressive cerebellar ataxia with concomitant hyper- and hypokinetic movement disorders, severe early-onset cerebellar atrophy, and in part olivary and brainstem degeneration. Patient fibroblasts showed a lack of PRDX3 protein, resulting in decreased glutathione peroxidase activity and decreased mitochondrial maximal respiratory capacity. Moreover, PRDX3 knockdown in cerebellar medulloblastoma cells resulted in significantly decreased cell viability, increased H2O2 levels and increased susceptibility to apoptosis triggered by reactive oxygen species. Pan-neuronal and pan-glial in vivo models of Drosophila revealed aberrant locomotor phenotypes and reduced survival times upon exposure to oxidative stress.  Our findings reveal a central role for mitochondria and the implication of oxidative stress in PRDX3 disease pathogenesis and cerebellar vulnerability and suggest targets for future therapeutic approaches.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  PRDX3; ROS; ataxia

Year:  2021        PMID: 33889951     DOI: 10.1093/brain/awab071

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  3 in total

1.  A novel biallelic variant further delineates PRDX3-related autosomal recessive cerebellar ataxia.

Authors:  Misbahuddin M Rafeeq; Muhammad Umair; Muhammad Bilal; Alaa Hamed Habib; Ahmed Waqas; Ziaullah M Sain; Mohammad Zubair Alam; Raja Hussain Ali
Journal:  Neurogenetics       Date:  2022-10-03       Impact factor: 3.017

2.  Common methods in mitochondrial research (Review).

Authors:  Yiyuan Yin; Haitao Shen
Journal:  Int J Mol Med       Date:  2022-08-25       Impact factor: 5.314

Review 3.  The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias.

Authors:  Andreas Traschütz; Selina Reich; Astrid D Adarmes; Mathieu Anheim; Mahmoud Reza Ashrafi; Jonathan Baets; A Nazli Basak; Enrico Bertini; Bernard Brais; Cynthia Gagnon; Janina Gburek-Augustat; Hasmet A Hanagasi; Anna Heinzmann; Rita Horvath; Peter de Jonghe; Christoph Kamm; Peter Klivenyi; Thomas Klopstock; Martina Minnerop; Alexander Münchau; Mathilde Renaud; Richard H Roxburgh; Filippo M Santorelli; Tommaso Schirinzi; Deborah A Sival; Dagmar Timmann; Stefan Vielhaber; Michael Wallner; Bart P van de Warrenburg; Ginevra Zanni; Stephan Zuchner; Thomas Klockgether; Rebecca Schüle; Ludger Schöls; Matthis Synofzik
Journal:  Front Neurol       Date:  2021-06-25       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.